Number of children with time off from school during · healthy, community‐dwelling children younger than 16 years of age
It is very uncertain whether live attenuated influenza vaccine changes number of children with time off from school during compared with placebo or do nothing (very low certainty).
1 finding from 1 review
Number of parents having to take off work during · healthy, community‐dwelling children younger than 16 years of age
Live attenuated influenza vaccine showed no clear difference in number of parents having to take off work during compared with placebo or do nothing (low certainty).
1 finding from 1 review
Hospitalisation ‐ not reported · healthy, community‐dwelling children younger than 16 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fever · healthy, community‐dwelling children younger than 16 years of age
1 finding from 1 review
Nausea ‐ not reported · healthy, community‐dwelling children younger than 16 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Influenza assessed by laboratory confirmation · healthy, community‐dwelling children older than 2 years of age
Inactivated influenza vaccine leads to lower influenza assessed by laboratory confirmation compared with placebo or do nothing (high certainty).
1 finding from 1 review
Death ‐ in all participants ‐ short term · people suspected to have meningococcal disease (adults and children)
Ceftriaxone showed no clear difference in death ‐ in all participants ‐ short term compared with long‐acting (oily) chloramphenicol (moderate certainty).
1 finding from 1 review
Death ‐ in confirmed cases of meningococcal meningitis (subgroup) · people suspected to have meningococcal disease (adults and children)
Ceftriaxone showed no clear difference in death ‐ in confirmed cases of meningococcal meningitis (subgroup) compared with long‐acting (oily) chloramphenicol (moderate certainty).
1 finding from 1 review
Clinical failure ‐ in all participants ‐ short term Composite clinical criteria10 · people suspected to have meningococcal disease (adults and children)
Ceftriaxone showed no clear difference in clinical failure ‐ in all participants ‐ short term Composite… compared with long‐acting (oily) chloramphenicol (moderate certainty).
1 finding from 1 review
Clinical failure ‐ in confirmed cases of meningococcal meningitis (subgroup) Composite clinical criteria10 · people suspected to have meningococcal disease (adults and children)
Ceftriaxone showed no clear difference in clinical failure ‐ in confirmed cases of meningococcal meningitis… compared with long‐acting (oily) chloramphenicol (moderate certainty).
1 finding from 1 review
Neurological sequelae ‐ in all participants‐ short term Clinical assessment11 · people suspected to have meningococcal disease (adults and children)
Ceftriaxone showed no clear difference in neurological sequelae ‐ in all participants‐ short term Clinical… compared with long‐acting (oily) chloramphenicol (low certainty).
1 finding from 1 review
Neurological sequelae ‐ in confirmed cases of meningococcal meningitis (subgroup) Clinical assesment11 · people suspected to have meningococcal disease (adults and children)
It is very uncertain whether ceftriaxone changes neurological sequelae ‐ in confirmed cases of meningococcal… compared with long‐acting (oily) chloramphenicol (very low certainty).
1 finding from 1 review
Adverse events ‐ short term · people suspected to have meningococcal disease (adults and children)
1 finding from 1 review
Intervention not reported
Acute exacerbations (number of exacerbations/person/year) · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
The intervention showed no clear difference in acute exacerbations (number of exacerbations/person/year) (low certainty).
1 finding from 1 review
Intervention not reported
Mortality (deaths during trial period) · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
It is very uncertain whether the intervention changes mortality (deaths during trial period) (very low certainty).
1 finding from 1 review
Intervention not reported
Carriage of NTHi Not meta‐analysed · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Hospital admissions (number of participants hospitalised during trial period) · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Intervention not reported
Adverse events (number of adverse events/person/year) · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
The intervention showed no clear difference in adverse events (number of adverse events/person/year) (low certainty).
1 finding from 1 review
Intervention not reported
Quality of life Not meta‐analysed · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Final diagnosis of at least one episode of AOM · infants and children
Influenza vaccine showed no clear difference in at least 1 episode of acute otitis media compared with control (low certainty).
1 finding from 1 review